IPO Timeline Raw facts
Broker Deadline
2024-10-28
Morning deadline
HKEX Deadline
2024-10-28
Noon deadline
Broker Results (T-2)
2024-10-29
Some brokers release in afternoon
Grey Market (T-1)
2024-10-30
Afternoon
HKEX Allotment (T-1)
2024-10-30
Evening
Registrar Allotment (T-1)
2024-10-30
Evening
Listing Day (T)
2024-10-31
First day of trading
Company Overview
| Stock Name | Biostar Pharm-B |
|---|---|
| Stock Code | 02563 |
| Company Full Name | Beijing Biostar Pharmaceuticals Co., Ltd. |
| Industry | 醫療保健 |
| Principal Activities | 公司是由留美科學家團隊創立的國家級高新技術企業，依托先進且可持續的合成生物學新藥研發平臺，專注于開發具有自主知識產權的抗癌新藥，經過20余年的發展，公司已成為集新藥研發、生產和商業化為一體的整合型生物醫藥公司。 |
| Listing Date | 2024-10-31 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國北京市北京經濟技術開發區亦城財富中心B座1202室 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | https://www.biostar-pharm.com/ |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | 18A生物科技 |
|---|---|
| Offer Price | HK$ 16.00 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | No |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 76.2% |
| Clawback Tiers | To be extracted |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 28,009,600 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 200 | HK$ 3,200 |
| 2 lots | 400 | HK$ 6,400 |
| 3 lots | 600 | HK$ 9,600 |
| 4 lots | 800 | HK$ 12,800 |
| 5 lots | 1,000 | HK$ 16,000 |
| 6 lots | 1,200 | HK$ 19,200 |
| 7 lots | 1,400 | HK$ 22,400 |
| 8 lots | 1,600 | HK$ 25,600 |
| 9 lots | 1,800 | HK$ 28,800 |
| 10 lots | 2,000 | HK$ 32,000 |
| 15 lots | 3,000 | HK$ 48,000 |
| 20 lots | 4,000 | HK$ 64,000 |
| 25 lots | 5,000 | HK$ 80,000 |
| 30 lots | 6,000 | HK$ 96,000 |
| 35 lots | 7,000 | HK$ 112,000 |
| 40 lots | 8,000 | HK$ 128,000 |
| 45 lots | 9,000 | HK$ 144,000 |
| 50 lots | 10,000 | HK$ 160,000 |
| 100 lots | 20,000 | HK$ 320,000 |
| 150 lots | 30,000 | HK$ 480,000 |
| 200 lots | 40,000 | HK$ 640,000 |
| 250 lots | 50,000 | HK$ 800,000 |
| 300 lots | 60,000 | HK$ 960,000 |
| 350 lots | 70,000 | HK$ 1,120,000 |
| 400 lots | 80,000 | HK$ 1,280,000 |
| 450 lots | 90,000 | HK$ 1,440,000 |
| 500 lots | 100,000 | HK$ 1,600,000 |
| 750 lots | 150,000 | HK$ 2,400,000 |
| 1,000 lots | 200,000 | HK$ 3,200,000 |
| 1,250 lots | 250,000 | HK$ 4,000,000 |
| 1,500 lots | 300,000 | HK$ 4,800,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 2,000 lots | 400,000 | HK$ 6,400,000 |
| 2,250 lots | 450,000 | HK$ 7,200,000 |
| 2,500 lots | 500,000 | HK$ 8,000,000 |
| 2,750 lots | 550,000 | HK$ 8,800,000 |
Stock Connect Inclusion
| HK Market Cap | HK$ 2.02B |
|---|
| 26Q2 Regular Review | |
| Inclusion Pathway | 18A Biotech |
|---|---|
| Est. Threshold | HK$ 10.47B Market cap gap 81% |
| Analysis Result | Market cap below threshold (gap 81%) |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | RMB 38.09 million |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | ~15.6% |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 20.8 |
|---|---|
| First Day Open | HK$ 21.5 |
| First Day Change | 30.00% |
| First Day Volume | 3185800.0 |
| First Day Turnover | 69538800.0 |
Use of Proceeds
| Use of Proceeds | 1、約44.9%或105.1百萬港元，將用于資助核心產品的進行中及計劃進行的臨床試驗； 2、約38.9%或91.1百萬港元，將用于資助核心產品以外的進行中及計劃進行的臨床試驗及產品臨床前研究以及核心產品研究者發起的試驗； 3、約3.0%或7.0百萬港元，將用于加強公司的國內商業化能力及建立公司的全球營銷網絡； 4、約3.2%或7.4百萬港元，將用于擴大產能； 5、約10.0%或23.4百萬港元，將用作營運資金及一般公司用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (2)
Overall Coordinators (2)
Joint Bookrunners (16)
CCB International Capital Limited CE AJO225
China Securities (International) Corporate Finance Company Limited CE BAU112
ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299
CMBC SECURITIES COMPANY LIMITED CE APU820
SPDB International Capital Limited CE BFZ375
China Galaxy International Securities (Hong Kong) Co., Limited CE AXM459
SHENWAN HONGYUAN SECURITIES (H.K.) LIMITED CE AAC927
ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855
Orient Securities (Hong Kong) Limited CE AVD362
Fosun International Securities Limited CE AAF432
GUOYUAN SECURITIES BROKERAGE (HONG KONG) LIMITED CE AOA594
SHANXI SECURITIES INTERNATIONAL LIMITED CE BEM330
First Shanghai Securities Limited CE ABV488
PATRONS SECURITIES LIMITED CE BPQ161
MOUETTE SECURITIES COMPANY LIMITED CE BLE877
CITRUS SECURITIES LIMITED CE BPX754
Joint Lead Managers (17)
CCB International Capital Limited CE AJO225
China Securities (International) Corporate Finance Company Limited CE BAU112
ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299
CMBC SECURITIES COMPANY LIMITED CE APU820
SPDB International Capital Limited CE BFZ375
China Galaxy International Securities (Hong Kong) Co., Limited CE AXM459
SHENWAN HONGYUAN SECURITIES (H.K.) LIMITED CE AAC927
ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855
Orient Securities (Hong Kong) Limited CE AVD362
Fosun International Securities Limited CE AAF432
GUOYUAN SECURITIES BROKERAGE (HONG KONG) LIMITED CE AOA594
SHANXI SECURITIES INTERNATIONAL LIMITED CE BEM330
First Shanghai Securities Limited CE ABV488
PATRONS SECURITIES LIMITED CE BPQ161
MOUETTE SECURITIES COMPANY LIMITED CE BLE877
CITRUS SECURITIES LIMITED CE BPX754
Futu Securities International (Hong Kong) Limited CE AZT137
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Novotech SG Holdings Pte. Ltd. | 23,081,600 HKD | — | 9.89% | — | 6 months | 2025-04-30 |
| 2 | Silky Water Absolute Return LPF | 61,555,200 HKD | — | 26.37% | — | 6 months | 2025-04-30 |
| 3 | 百洋健康产业国际商贸有限公司 | 15,376,000 HKD | — | 6.59% | — | 6 months | 2025-04-30 |
| 4 | 富策控股有限公司 | 77,721,600 HKD | — | 33.30% | — | 6 months | 2025-04-30 |
Directors & Management
| Chairman | 唐莉 |
|---|---|
| Company Secretary | 劉開林,陳奕斌 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | Baygen QT Inc.(11.11%),珠海京蓉昊緣投資合伙企業(有限合伙)(5.59%),珠海華錦昊緣企業管理合伙企業(有限合伙)(5.27%) |
|---|
AI
AI 市场洞察
AI interpretation
deepseek-v4-pro · AI-generated
市场情绪
The IPO saw a moderate oversubscription of 21.45 times, reflecting steady but not frenzied demand. The overall hit rate of 27.47% is relatively high, indicating ample allocation for most applicants. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
申购档位分析
A-tail applicants applying HKD 200,000 were allocated an expected 0.4444 lots, nearly identical to B-head applicants with HKD 250,000 who received 0.4615 lots, making the marginal benefit of the higher tier negligible. Given the clawback reallocation, this inefficiency suggests B-head may incur higher broker fees for minimal extra allocation. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
申购人群画像
The demographic breakdown shows zero participants recorded for both mainland and Hong Kong categories, likely due to data limitations, so no regional or demographic trends can be inferred. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
